Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.54 |
| ▸ | HTR3A | P46098 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | WNT1 | P04628 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710407 | 1.00 | SMYD3 (1.00) | SMYD3NPC1RAB9AUSP30CHRNA7 | |
| SCHEMBL19710468 | 0.85 | NPC1 (0.78) | SMYD3NPC1RAB9AUSP30CHRNA7 | |
| SCHEMBL21489892 | 0.85 | NPC1 (0.78) | SMYD3NPC1RAB9AUSP30CHRNA7 | |
| SCHEMBL30068489 | 0.84 | NPC1 (0.80) | SMYD3NPC1RAB9AUSP30CHRNA7 | |
| SCHEMBL4384530 | 0.82 | NPC1 (0.82) | SMYD3NPC1RAB9AUSP30CHRNA7 | |
| SCHEMBL26400414 | 0.82 | NPC1 (0.97) | SMYD3NPC1RAB9AUSP30CHRNA7 | |
| SCHEMBL29732688 | 0.78 | NPC1 (0.74) | SMYD3NPC1RAB9AUSP30CHRNA7 | |
| SCHEMBL6950689 | 0.78 | NPC1 (0.74) | SMYD3NPC1RAB9AUSP30CHRNA7 | |
| SCHEMBL21489781 | 0.77 | SMYD3 (0.70) | SMYD3NPC1RAB9AHDAC3HDAC1 | |
| SCHEMBL19710071 | 0.77 | SMYD3 (0.70) | SMYD3NPC1RAB9AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885NPC1 3734/4885RAB9A 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.